SNG Share PerformanceMore
|52 week high||38.00 25/04/16|
|52 week low||19.00 01/03/16|
|52 week change||2.00 (6.45%)|
|4 week volume||578,905 04/09/16|
Media for (SNG)
Latest News« previous» nextMore
22/09/2016 - 13:30 StockMarketWire
N+1 Singer today reaffirms its buy investment rating on Synairgen PLC (LON:SNG) and cut its price target to 46p (from 4...
22/09/2016 - 09:50 StockMarketWire
Synairgen has widened its H1 pretax loss to 1.7m, from a year-earlier loss of 1.0m. Revenue was nil, from 25,000. "We are ve...
22/09/2016 - 07:00 RNS
RNS Number: 5051K Synairgen plc 22 September 2016 Press release Synairgen plc ('Synairgen' or the 'Company') Interim results for the six months ended 30 June 2016 ~ Clinical development of AZD9412 with AstraZeneca on track and Pharmaxis collaboration progressing towards the clinic ~ Southampton, UK - 22 September 2016: Synairgen plc (LSE: SNG), the respir...
08/09/2016 - 07:00 RNS
RNS Number: 2364J Synairgen plc 08 September 2016 PRESS RELEASE 8 September 2016 SYNAIRGEN PLC ("Synairgen" or "the Company") Notice of Interim Results Southampton, UK, 8 September 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, will issue its interim results for the six-month period ended 30 June 2016 o...
14/06/2016 - 12:00 RNS
RNS Number: 1527B Synairgen plc 14 June 2016 PRESS RELEASE 14 June 2016 SYNAIRGEN PLC ("Synairgen" or "the Company") Result of Annual General Meeting Southampton, UK, 14 June 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce that all resolutions proposed at its Annual General Meeting...
07/06/2016 - 12:35 Motley Fool
Junior pharmaceutical stocks have the potential to create huge value for shareholders if successful. These two stocks both h...
17/05/2016 - 07:00 RNS
RNS Number: 4029Y Synairgen plc 17 May 2016 PRESS RELEASE 17 May 2016 SYNAIRGEN PLC ("Synairgen" or "the Company") Southampton, UK, 17 May 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that on 16 May 2016 it posted its full Audited Report and Accounts for the twelve months ended 31 Decem...
21/04/2016 - 14:14 RNS
RNS Number: 9600V Synairgen plc 21 April 2016 Synairgen plc ('Synairgen' or the 'Company') Holding in Company Southampton, UK,: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it received notice on 20 April 2016 that Leonard Licht, a private investor, holds 2,775,000 ordinary shares of 1 pence each in the capi...
|Dividend yield||0 %|
Equity Research (SNG)
The recent exclusive global deal with AstraZeneca, potentially worth $230m, to in-license SNG001 for the treatment of asthma is a strong validation of Synairgen’s in-vitro cell-based approach using...
Latest discussion posts More
“... and the higher the better!!”▼
“Nice to see a move up Would repeat. This is Fincap target price-also to note-Woodford now 22% & Richard griffiths 10% These two holders increased their stakes in ...”▼
“Should have put Buy Not Sell in header-pushed wrong button -whoops.”▼
Codes & Symbols
|Symbols||SNG, LSE:SNG, SNG.L, SNG:LN, LON:SNG, XLON:SNG|